Datapoint: Sarclisa to Compete with Darzalex in Multiple Myeloma

The FDA last week approved Sanofi’s Sarclisa (in tandem with Amgen’s Kyprolis and dexamethasone) for the treatment of relapsed or refractory multiple myeloma in patients who have had at least one prior treatment. This will put Sarclisa in direct competition with Johnson & Johnson’s Darzalex, which scored the same indication in August 2020. For the treatment of multiple myeloma, Darzalex currently holds preferred formulary placement for 7% of covered lives, growing to 17% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 4/5/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 27

Datapoint: FDA Approves First Interchangeable Humira Biosimilar

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 26

Datapoint: Oscar Partners With Colorado Health Systems in Statewide Expansion Effort

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today